Browse > Article
http://dx.doi.org/10.4014/kjmb.1407.07005

Effect on Immune Cells of Proteoglycan Originating from Rhanella aquatilis  

Park, Hae-Gi (Department of Life Science and Biotechnology, Dong-eui University)
Kim, Kwang-Hyeon (Department of Life Science and Biotechnology, Dong-eui University)
Publication Information
Microbiology and Biotechnology Letters / v.42, no.3, 2014 , pp. 312-315 More about this Journal
Abstract
So as to evaluate its use an immune stimulator in humans, the toxicity and action against immune cells by an anti-yeast substance (AYS), a bacterial proteoglycan, were investigated. The AYS did not possess hemolytic activity with human red blood cells (hRBC). Nor did it exhibit cytotoxicity against human peripheral blood mononuclear cells (hPBMC). In addition, the AYS did not induce hPBMC proliferation, but it did agglutinate hPBMCs in vitro. Moreover, hPBMC induced inflammatory cytokines such as IL-6, IL-5, IFN-${\gamma}$ and TNF-${\alpha}$ with the AYS during culture. Compared with alum, the AYS as an adjuvant has an increased antibody production rate against bovine serum albumin (BSA) in mice.
Keywords
Rhanella aquatilis; proteoglycan; leuko-agglutinin; inflammatory cytokine; antibody production;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Schijns VE, Lavelle EC. 2011. Trends in vaccine adjuvants. Expert. Rev. Vaccines 10: 539.   DOI   ScienceOn
2 Tomljenovic L, Shaw CA. 2012. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatiric populations. Lupus 21: 223-230.   DOI
3 Wang W, Singh M. 2011. Selection of adjuvants for enhanced vaccine potency. World J. Vaccines 1: 33-78.   DOI
4 Alan J, Robin T. 1982. Immunochemistry in practice. pp. 257-260. 2nd Ed. Blackwell Scientific Publications, London.
5 Alexander BD, Erik BL, Ernesto OO. 2011. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol. Lett. 203: 97-105.   DOI
6 Ciapetti G, Cenni E, Pratelli L, Pizzoferrato A. 1993. In vitro evaluation of cell/biomaterial interaction by MTT assay. Biomaterials 14: 359-364.   DOI   ScienceOn
7 Higgins D, Marshall JD, Traquinia P, Van Nest G, Livingston BD. 2007. Immunostimulatory DNA as a vaccine adjuvant. Expert. Rev. Vaccines 6: 747-759.   DOI   ScienceOn
8 Khajuria A, Gupta A, Malik F, Singh S, Singh J, Gupta BD, et al. 2007. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine 25: 4586-4594.   DOI
9 Lingnau K, Riedl K, von Gabain A. 2007. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev. Vaccines 6: 741-746.   DOI
10 Mbow ML, de Gregorio E, Ulmer JB. 2011. Alum's adjuvant action: grease is the word. Nat. Med. 17: 415-416.   DOI
11 Muller BW, Bock T. 1994. A novel assay to determine the hemolytic activity of drug incorporated in colloidal carriers systems. Pharm. Res. 11: 589-591.   DOI
12 O'Hagan DT, Ott GS, de Gregorio E, Seubert A. 2012. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341.   DOI   ScienceOn
13 Park HJ, Kang MJ, Lee JH, Kim KH. 2011. Action pattern of anti-yeast substance originated from Rhanella aquatilis strain AY2000. Korean J. Microbiol. 47: 163-166.